RBL 001/RBL 002/RBL 003/RBL 004

Drug Profile

RBL 001/RBL 002/RBL 003/RBL 004

Alternative Names: Lipo-MERIT; RB 0003; RB_0003; RBL001.1/RBL002.2/RBL003.1/RBL004.1; RBL001/RBL002/RBL003/RBL004; RNA-LPX; RNA(LIP); Tetravalent RNA-lipoplex Cancer Vaccine

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioNTech
  • Class Cancer vaccines; RNA vaccines; Synthetic vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma

Most Recent Events

  • 27 Sep 2017 Preliminary immunogenicity data from a phase I trial in Malignant melanoma presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
  • 21 Aug 2017 Phase I/II development is ongoing in Germany (NCT02410733)
  • 01 Mar 2015 Phase-I/II clinical trials in Malignant melanoma in Germany (IV) (NCT02410733,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top